Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Telix Pharmaceuticals.
RELATED STOCKHEAD STORIES
Health & Biotech
Top ASX biotechs catching the eye of analysts and fund managers in 2024 – Part 1
Health & Biotech
ASX Health Stocks: Island Pharma releases data on dengue fever drug, IDT signs $3m+ deal with Sanofi
News
ASX Small Caps and IPO Weekly Wrap: Gold and medicine are the best medicine
News
Closing Bell: ASX goes missing as new premiums lift health stocks; Bitcoin at US$68k
News
ASX Large Caps: AI craze sweeps ASX; Block Inc, Aussie Broadband up 17pc, Newmont dips 7pc
Health & Biotech
ASX Health Stocks: Cochlear upgrades guidance, Chimeric up 12pc after commencing Phase 1B trial on leukaemia
Health & Biotech
ScoPo’s Powerplays: ASX healthcare 0.3% up as focus shifts to M&A activity in 2024
Health & Biotech
ASX Health Stocks: US bound Telix plans dual listing on the NASDAQ
News
Market Highlights: Magnificent 7 all at sea in New York as iron ore trades higher
Health & Biotech
ASX Health Stocks: dorsaVi up 27pc on US deals, Starpharma reports positive outcome on Phase 2 trial
Experts
The Wulff: It’s time to meet the ASX Sectors of the Year
News
ASX Large Caps: Commodity stocks push ASX higher, Telstra down 2pc on expansion plan
News
ASX Large Caps: Rates sensitive stocks rally hard; Origin Energy slumps on rejected offer
News
ASX Large Caps: ASX slumps 1.5pc as gold stocks rally on safe-haven flight; jobless rate unexpectedly up
Health & Biotech
ASX Health Stocks: Telix tumbles 17pc, Emyria to import MDMA after approval in Canada
Health & Biotech
Global biotech sector set to boom but where are Aussie investors?
Explainers
